Markets:

Overview

News

Currencies

International

Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.775 +0.155 (+5.92%)

Delayed Quote Updated: 3:09 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy ↗

September 11, 2026

Editas Medicine (NASDAQ:EDIT) outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for...

Via MarketBeat

Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401 ↗

September 09, 2026

Editas Medicine (NASDAQ:EDIT) is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial...

Via MarketBeat

Wondering what's happening in today's after-hours session? ↗

August 31, 2026

Via Chartmill

Editas Medicine (NASDAQ:EDIT) Beats Q2 Estimates, but One-Time Revenue Boost Masks Underlying Momentum ↗

August 05, 2026

Via Chartmill

Earnings Scheduled For May 12, 2025 ↗

May 12, 2025

Via Benzinga

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? ↗

May 31, 2026

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.

Via The Motley Fool

Which stocks are moving before the opening bell on Tuesday? ↗

May 26, 2026

Via Chartmill

Is Editas Medicine Going to $0? ↗

March 17, 2026

The biotech could run out of funding before it can launch a single product.

Via The Motley Fool

Editas (EDIT) Q2 2024 Earnings Call Transcript ↗

November 27, 2025

Editas (EDIT) Q2 2024 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Editas Medicine Inc (NASDAQ:EDIT) Beats Q3 2025 Estimates and Provides Key Pipeline Update ↗

November 10, 2025

Editas Medicine beats Q3 2025 earnings estimates, reports strong revenue growth, and advances its lead gene-editing program, EDIT-401.

Via Chartmill

AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures

November 06, 2025

A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as...

Via TokenRing AI

Topics Artificial Intelligence Climate Change Intellectual Property

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗

October 27, 2025

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event.

Via Benzinga

Editas Medicine Inc (NASDAQ:EDIT) Shows High Growth Momentum and Strong Technical Trend ↗

October 07, 2025

Editas Medicine (EDIT) stock shows strong technical uptrends and explosive 597% revenue growth, making it a top pick for momentum investors.

Via Chartmill

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗

September 18, 2025

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.

Via Benzinga

Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

September 05, 2025

Via Benzinga

Why Editas Medicine Stock Was Skyrocketing This Week ↗

August 15, 2025

The company's CEO made quite the encouraging statement regarding its immediate future.

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 13, 2025

Via Benzinga

Top movers in Wednesday's session ↗

August 13, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Wednesday's session: gap up and gap down stocks ↗

August 13, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

Editas Medicine Inc (NASDAQ:EDIT) Reports Mixed Q2 2025 Earnings: Revenue Beat but Wider Loss ↗

August 12, 2025

Editas Medicine posted Q2 2025 revenue of $3.58M, beating estimates, but EPS loss widened to -$0.63. Stock dipped 1.75% amid restructuring concerns. Pipeline progress includes IND filing plans for...

Via Chartmill

Can This Beaten-Down Stock Bounce Back? ↗

August 12, 2025

This small-cap biotech is seeking to develop breakthrough therapies, but so far it's found little success.

Via The Motley Fool

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? ↗

June 28, 2025

Via The Motley Fool

Topics Workforce

2 Beaten-Down Stocks to Avoid ↗

June 27, 2025

Via The Motley Fool

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗

June 18, 2025

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Via Benzinga

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. ↗

June 17, 2025

Via The Motley Fool

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover ↗

June 17, 2025

The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.

Via Investor's Business Daily

1 Stock Down 97% That Could Double, According to Wall Street ↗

May 25, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 21, 2025

Via Benzinga

Editas Medicine: A Cautionary Tale for Investors ↗

May 15, 2025

Via The Motley Fool

The Future of Healthcare: 10 Predictions For The Next Decade

March 27, 2025

The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we...

Via MarketMinute

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.